Vistide(cidofovir)
Vistide (cidofovir) is a small molecule pharmaceutical. Cidofovir was first approved as Vistide on 1996-06-26. It is used to treat aids-related opportunistic infections, cytomegalovirus infections, and cytomegalovirus retinitis in the USA. It has been approved in Europe to treat cytomegalovirus retinitis.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| eye diseases | D005128 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Cidofovir (discontinued: Vistide)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cidofovir
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VISTIDE | Gilead Sciences | N-020638 DISCN | 1996-06-26 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cidofovir | ANDA | 2021-04-15 |
| cidofovir dihydrate | ANDA | 2023-10-25 |
| vistide | New Drug Application | 2013-09-24 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| cytomegalovirus infections | EFO_0001062 | D003586 | B25 |
| aids-related opportunistic infections | — | D017088 | — |
| cytomegalovirus retinitis | EFO_1001302 | D017726 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0740 | Injection, cidofovir, 375 mg |
Clinical
Clinical Trials
42 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 3 | 3 | 2 | 1 | 5 | 13 |
| Cytomegalovirus retinitis | D017726 | EFO_1001302 | — | 1 | 3 | 2 | 2 | 4 | 11 |
| Retinitis | D012173 | — | H30.9 | 1 | 3 | 2 | 2 | 4 | 11 |
| Respiratory tract infections | D012141 | — | J06.9 | — | 1 | — | 1 | 2 | 4 |
| Papillomavirus infections | D030361 | — | — | — | 1 | 1 | 1 | 1 | 4 |
| Papilloma | D010212 | — | — | 1 | 1 | — | 1 | 1 | 4 |
| Recurrence | D012008 | — | — | — | 1 | — | 1 | 1 | 3 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | 2 | 1 | 2 | — | 1 | 6 |
| Cytomegalovirus infections | D003586 | EFO_0001062 | B25 | 1 | 1 | 2 | — | 1 | 5 |
| Communicable diseases | D003141 | — | — | 1 | 1 | 1 | — | 1 | 4 |
| Herpes simplex | D006561 | — | B00 | 1 | — | 1 | — | 2 | 4 |
| Cytomegalovirus | D003587 | — | — | — | — | 2 | — | 1 | 3 |
| Neoplasms | D009369 | — | C80 | 1 | — | 1 | — | 1 | 3 |
| Squamous intraepithelial lesions of the cervix | D065310 | — | — | — | 2 | 1 | — | — | 3 |
| Carcinoma in situ | D002278 | — | D09.9 | — | 1 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adenoviridae infections | D000257 | EFO_1001259 | B34.0 | — | 3 | — | — | 1 | 4 |
| Adenoviridae | D000256 | — | — | — | 2 | — | — | 1 | 3 |
| Cystitis | D003556 | EFO_1000025 | N30 | 1 | 1 | — | — | 1 | 3 |
| Hemorrhagic cystitis | D000096722 | — | — | 1 | 1 | — | — | 1 | 3 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | 1 | — | — | 1 | 3 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | 1 | — | — | 1 | 2 |
| Precancerous conditions | D011230 | — | — | 1 | 1 | — | — | — | 2 |
| Viremia | D014766 | — | B34.9 | — | 1 | — | — | — | 1 |
| Squamous cell carcinoma | D002294 | — | — | — | 1 | — | — | — | 1 |
| Warts | D014860 | — | B07 | — | 1 | — | — | — | 1 |
Show 5 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Uterine cervical neoplasms | D002583 | HP_0030159 | — | 3 | — | — | — | — | 3 |
| Hematopoietic stem cell transplantation | D018380 | — | — | 1 | — | — | — | — | 1 |
| Cervical intraepithelial neoplasia | — | — | D06 | 1 | — | — | — | — | 1 |
| Uterine cervical dysplasia | D002578 | EFO_1000910 | N87 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Condylomata acuminata | D003218 | EFO_0007147 | A63.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Papillomaviridae | D027383 | — | — | — | — | — | — | 1 | 1 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | — | — | 1 | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | — | 1 | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
| Sepsis | D018805 | HP_0100806 | A41.9 | — | — | — | — | 1 | 1 |
| Neutropenia | D009503 | — | D70 | — | — | — | — | 1 | 1 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | — | 1 | 1 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 1 | 1 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | — | — | 1 | 1 |
Show 46 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cidofovir |
| INN | cidofovir |
| Description | Cidofovir anhydrous is cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients. It has a role as an antiviral drug, an antineoplastic agent, an anti-HIV agent and a photosensitizing agent. It is a pyrimidone and a member of phosphonic acids. It is a conjugate acid of a cidofovir(2-) and a cidofovir(1-). |
| Classification | Small molecule |
| Drug class | antivirals |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ccn(C[C@@H](CO)OCP(=O)(O)O)c(=O)n1 |
Identifiers
| PDB | — |
| CAS-ID | 113852-37-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL152 |
| ChEBI ID | 3696 |
| PubChem CID | 60613 |
| DrugBank | DB00369 |
| UNII ID | 768M1V522C (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,289 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cidofovir, Cidofovir dihydrate, Vistide
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
890 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use